Becton, Dickinson and Company

Equities

BDX

US0758871091

Medical Equipment, Supplies & Distribution

Market Closed - Nyse 04:00:02 2024-03-28 pm EDT 5-day change 1st Jan Change
247.4 USD +0.37% Intraday chart for Becton, Dickinson and Company +2.41% +1.48%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Sector Update: Health Care Stocks Higher in Late Afternoon Trading MT
Sector Update: Health Care Stocks Higher in Afternoon Trading MT
Sector Update: Health Care MT
Becton, Dickinson Raising Domestic Production of Syringes MT
Transcript : Becton, Dickinson and Company Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 09:30 AM
Becton, Dickinson and Co. Enrolls First Person in Trial of Stent to Treat Peripheral Arterial Disease MT
Becton, Dickinson and Company Initiates International Study to Expand Treatment Options for Patients with Peripheral Arterial Disease CI
Transcript : Becton, Dickinson and Company Presents at Citi?s 2024 Unplugged Medtech and Life Sciences Access Day, Feb-29-2024 08:00 AM
Dave Hickey Retires as Executive Vice President and President of the Life Sciences Segment for BD, Effective from July 1, 2024 CI
Becton, Dickinson Seeks M&A CI
Transcript : Becton, Dickinson and Company - Special Call
Becton, Dickinson Collaborating With Camtech Health for at-Home Cervical Cancer Screening in Singapore MT
Barclays Adjusts Price Target on Becton Dickinson and Co. to $305 From $301, Maintains Overweight Rating MT
Tranche Update on Becton, Dickinson and Company's Equity Buyback Plan announced on November 4, 2021. CI
Sector Update: Health Care Stocks Edge Higher Premarket Thursday MT
Transcript : Becton, Dickinson and Company, Q1 2024 Earnings Call, Feb 01, 2024
Becton, Dickinson's Fiscal Q1 Adjusted Earnings Down, Revenue Up; 2024 Guidance Revised MT
Becton Dickinson Lifts 2024 Outlook After Sales Rise in 1Q DJ
(BDX) BD (BECTON DICKINSON AND COMPANY) Sees Fiscal Year 2024 EPS Range $12.82 - $13.06 MT
Earnings Flash (BDX) BD (BECTON DICKINSON AND COMPANY) Posts Q1 Revenue $4.71B, vs. Street Est of $4.73B MT
Earnings Flash (BDX) BD (BECTON DICKINSON AND COMPANY) Posts Q1 EPS $2.68, vs. Street Est of $2.40 MT
Becton, Dickinson and Company Reports Earnings Results for the First Quarter Ended December 31, 2023 CI
Becton, Dickinson and Company Raises Earnings Guidance for the Fiscal Year of 2024 CI
North American Morning Briefing : Stock Futures -2- DJ
Becton, Dickinson Collaborating With Techcyte on AI-Based Cervical Cancer Testing MT
Chart Becton, Dickinson and Company
More charts
Becton, Dickinson and Company specializes in the development, manufacturing and marketing of medical and diagnostic equipment and materials. Net sales break down by family of products as follows: - medical equipment (73.5%): surgical instruments, urological care products, pharmaceutical systems, etc.; - diagnostic materials (18.7%): automated systems for blood testing, mycobacteria detection, and molecular biology, medical biology devices, etc.; - clinical research and development tools (7.8%): tools for discovering drugs and vaccines, studying genes, culturing cells, and manipulating liquids, instruments for sorting and analyzing cells, monoclonal antibodies, etc. Net sales are distributed geographically as follows: the United States (57.4%), Europe/Middle East/Africa (21.9%), Asia (15%) and other (5.7%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
247.4 USD
Average target price
283.1 USD
Spread / Average Target
+14.39%
Consensus
  1. Stock
  2. Equities
  3. Stock Becton, Dickinson and Company - Nyse
  4. News Becton, Dickinson and Company
  5. Becton Dickinson and : Reaches Injection Device Milestone in Support of Global COVID-19 Vaccination Drive